Yorkshire Collaborative Small Cell Lung Cancer Study
| ISRCTN | ISRCTN15654915 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15654915 |
| Protocol serial number | TH/SMC |
| Sponsor | Northern and Yorkshire Clinical Trials and Research Unit (UK) |
| Funder | Northern & Yorkshire Clinical Trials & Research Unit (UK) |
- Submission date
- 19/08/2002
- Registration date
- 19/08/2002
- Last edited
- 24/10/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr
Scientific
Scientific
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | Yorkshire Collaborative Small Cell Lung Cancer Study |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Lung (small cell) |
| Intervention | Good/moderate-prognosis patients: Patients receive chemotherapy with Ifosfamide, etoposide, mensa and vincristine (EIMV) for three courses. Patients with greater than 50% response are randomised to either: 1. Group A: No mandatory treatment, radiotherapy is optional. 2. Group B: Three further courses of EIMV chemotherapy plus optional radiotherapy. Poor-prognosis patients: Chemotherapy is at the physicians discretion. If chemotherapy is chosen single agent etoposide or EIMV chemotherapy is recommended. |
| Intervention type | Other |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 01/04/1995 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Key inclusion criteria | 1. Small cell lung cancer confirmed by histological or bronchial brush or aspirate cytology. 2. Aged <75 years 3. Normal renal and hepatic function 4. No evidence of brain metastases 5. No previous specific anti-cancer treatment for current disease 6. No other malignant disease, except basal cell carcinoma and in situ carcinoma of the cervix |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/01/1994 |
| Date of final enrolment | 01/04/1995 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
24/10/2019: No publications found. All search options exhausted.
